MA42667A - Compositions et systèmes multiplexés pour la transcription-traduction et la synthèse protéique couplées sans cellules et procédés pour les utiliser - Google Patents

Compositions et systèmes multiplexés pour la transcription-traduction et la synthèse protéique couplées sans cellules et procédés pour les utiliser

Info

Publication number
MA42667A
MA42667A MA042667A MA42667A MA42667A MA 42667 A MA42667 A MA 42667A MA 042667 A MA042667 A MA 042667A MA 42667 A MA42667 A MA 42667A MA 42667 A MA42667 A MA 42667A
Authority
MA
Morocco
Prior art keywords
multiplex
translation
compositions
cell
systems
Prior art date
Application number
MA042667A
Other languages
English (en)
Inventor
Nelson Barton
Ihsiung Brandon Chen
Stephanie Culler
Priti Pharkya
Dien Steve Van
Original Assignee
Genomatica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomatica Inc filed Critical Genomatica Inc
Publication of MA42667A publication Critical patent/MA42667A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/15Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA042667A 2015-08-20 2016-08-19 Compositions et systèmes multiplexés pour la transcription-traduction et la synthèse protéique couplées sans cellules et procédés pour les utiliser MA42667A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562207844P 2015-08-20 2015-08-20

Publications (1)

Publication Number Publication Date
MA42667A true MA42667A (fr) 2021-05-05

Family

ID=58051779

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042667A MA42667A (fr) 2015-08-20 2016-08-19 Compositions et systèmes multiplexés pour la transcription-traduction et la synthèse protéique couplées sans cellules et procédés pour les utiliser

Country Status (5)

Country Link
US (2) US20180237847A1 (fr)
EP (1) EP3337490A4 (fr)
CA (1) CA2994304A1 (fr)
MA (1) MA42667A (fr)
WO (1) WO2017031399A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3430153A1 (fr) * 2016-04-14 2019-01-23 DSM Sinochem Pharmaceuticals Netherlands B.V. Protéines type mbth dans des processus eucaryotes catalysés par nrps
IL308091B1 (en) 2016-09-13 2026-01-01 Allergan Inc Protein-free stabilized Clostridium toxin preparations
US20190376069A1 (en) * 2017-02-07 2019-12-12 The Regents Of The University Of California Use of microbial consortia in the production of multi-protein complexes
CN108374028B (zh) * 2017-02-27 2021-05-11 扬州大学 一种利用化学表观遗传修饰提高海洋真菌中azaphilone类化合物产量的方法
US20200109429A1 (en) * 2017-03-06 2020-04-09 Synvitrobio, Inc. Methods and Systems for Cell-Free Biodiscovery of Natural Products
CN106978471A (zh) * 2017-03-27 2017-07-25 海南大学 一种酰基转移酶标记的工程化噬菌体快速检测微生物
US20210108191A1 (en) * 2017-04-04 2021-04-15 The Board Of Trustees Of The University Of Illinois Methods of Production of Biologically Active Lasso Peptides
KR101969506B1 (ko) * 2017-05-04 2019-08-13 주식회사 앤코스메슈 곰보버섯 추출물을 유효성분으로 포함하며 항암효능을 갖는 혼합 조성물
CN109321620A (zh) * 2017-07-31 2019-02-12 康码(上海)生物科技有限公司 一种蛋白合成冻干制剂及其制备方法和应用
CN107602609B (zh) * 2017-08-31 2020-07-21 湖南理工学院 一种以p(o)-oh化合物与含甲基取代芳香烃制备有机磷酸酯类化合物的方法
US20230193337A1 (en) * 2017-10-19 2023-06-22 Synvitrobio, Inc. Anaerobic Cell-Free Systems and Environments and Methods for Making and Using Same
CN112739345A (zh) 2017-11-06 2021-04-30 斯奈普生物公司 Pim激酶抑制剂组合物,方法和其用途
GB2584211B (en) * 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions
WO2019127469A1 (fr) * 2017-12-29 2019-07-04 康码(上海)生物科技有限公司 Système énergétique de régénération à haut rendement (ser), kit et sa méthode de préparation
CN108192908A (zh) * 2018-01-29 2018-06-22 天津大学 利用筑波链霉菌提高他克莫司发酵产量的方法
CN108504669A (zh) * 2018-03-21 2018-09-07 天津大学 一种含小分子糖的体外高效合成蛋白质的系统
EP3774847A4 (fr) * 2018-03-30 2022-04-20 Lassogen, Inc. Procédés de production, de découverte et d'optimisation de peptides lasso
WO2019195655A1 (fr) * 2018-04-06 2019-10-10 University Of Florida Research Foundation, Incorporated Souches de streptomyces albus modifiées
US12173343B2 (en) * 2018-06-06 2024-12-24 Syngulon Sa Engineering antimicrobial peptides
GB201817971D0 (en) 2018-11-02 2018-12-19 British American Tobacco Investments Ltd Method
US10768173B1 (en) 2019-09-06 2020-09-08 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
CN111778222B (zh) * 2019-04-04 2024-03-22 中国科学院微生物研究所 一个能在真菌中产生黄酮类化合物的nrps-pks杂合蛋白及其编码基因与应用
CN109988219B (zh) * 2019-04-22 2020-06-05 云南大学 一种倍半萜环己烯酮类化合物及其制备方法和应用
CN110343639B (zh) * 2019-07-23 2021-04-27 中国医药集团总公司四川抗菌素工业研究所 一株产15(s)-o-乙基雷帕霉素的链霉菌
CN214973877U (zh) 2019-08-09 2021-12-03 胡桃钳医疗公司 用于形成治疗性多核苷酸的微流体设备及微流体路径装置
US11287422B2 (en) 2019-09-23 2022-03-29 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis
CN110643578B (zh) * 2019-10-25 2021-02-19 浙江工商大学 一株抗阿维拉霉素a单克隆抗体杂交瘤细胞株及其应用
CN110863002A (zh) * 2019-11-29 2020-03-06 武汉赛维尔生物科技有限公司 一种改造次级翻译起始位点使蛋白正确表达的方法
CA3166826A1 (fr) * 2020-01-06 2021-07-15 Lassogen, Inc. Peptides lassos pour le traitement du cancer
WO2021174199A1 (fr) * 2020-02-28 2021-09-02 Synvitrobio, Inc. Procédés et compositions pour identifier des caractères à l'aide d'un système acellulaire
CN113717909B (zh) * 2020-05-26 2024-11-05 杭州中美华东制药有限公司 一种达托霉素高产菌株及其应用
CN113046380A (zh) * 2021-03-19 2021-06-29 清华大学 一种基于σ因子作为转录元件的无细胞蛋白质合成方法
CN115612718A (zh) * 2021-07-13 2023-01-17 中国科学院北京基因组研究所(国家生物信息中心) 一种单细胞翻译组测序的方法
EP4573213A1 (fr) 2022-08-15 2025-06-25 Element Biosciences, Inc. Capture sur surface à résolution spatiale d'acides nucléiques
WO2025037122A1 (fr) 2023-08-16 2025-02-20 Nuclera Ltd Réactifs d'expression protéique
CN118834893A (zh) * 2024-08-26 2024-10-25 广东工业大学 基于艰难梭菌的无细胞基因表达体系

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480772A (en) * 1993-02-03 1996-01-02 Brandeis University In vitro activation of a nucleus
US6495348B1 (en) * 1993-10-07 2002-12-17 Regents Of The University Of Minnesota Mitomycin biosynthetic gene cluster
US20020142397A1 (en) * 2000-12-22 2002-10-03 Philippe Collas Methods for altering cell fate
AU2009245445B2 (en) * 2008-05-09 2013-09-26 Regenics As Cellular extracts
US20130316397A1 (en) * 2012-04-30 2013-11-28 The Board Of Trustees Of The Leland Standford Junior University Cell-Free Polypeptide Synthesis

Also Published As

Publication number Publication date
EP3337490A4 (fr) 2019-07-24
CA2994304A1 (fr) 2017-02-23
US20180237847A1 (en) 2018-08-23
US20230399688A1 (en) 2023-12-14
WO2017031399A1 (fr) 2017-02-23
EP3337490A1 (fr) 2018-06-27

Similar Documents

Publication Publication Date Title
MA42667A (fr) Compositions et systèmes multiplexés pour la transcription-traduction et la synthèse protéique couplées sans cellules et procédés pour les utiliser
IL272367A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
IL291604A (en) Stabilized soluble pre-fusion rsv f proteins
IL269209A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3302706A4 (fr) Compositions et procédés pour la dégradation de protéines mal pliées
LT3563250T (lt) Technologijos, skirtos saugiai išplėsti debesijos paslaugų api debesijos paslaugų rinkoje
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
EP3589662A4 (fr) Protéine monovalente inductible de fixation d' antigène
IL259713A (en) Anti-dr5 antibodies and methods of use thereof
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3541841T3 (da) Anti-PD-1-antistoffer og sammensætninger
IL263223A (en) Antibodies against cd40 and their uses
EP3503901A4 (fr) Procédés et compositions pour cellules de moelle épinière
DK3273992T3 (da) Antistoffer mod ICOS
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
EP3155018A4 (fr) Protéines de fusion à anticorps à région constante et compositions les contenant
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
EP3268050A4 (fr) Compositions de conjugués de protéines porogènes et procédés correspondants
CU20150117A7 (es) Inmunoterapia tau
EP3548073A4 (fr) Protéines de fusion pour l'appauvrissant sélective d'anticorps spécifiques d'un antigène
EP3350197A4 (fr) Procédés et systèmes de synthèse de peptide en phase solide
EP3529280A4 (fr) Anticorps dirigés contre les protéines mica et micb
EP2910076A4 (fr) Systèmes et procédés pour une synchronisation efficace de canaux
EP3256163A4 (fr) Méthodes et compositions pour moduler les protéines lilr
EP3288587A4 (fr) Modulation de réponse immunitaire au moyen d'anticorps agonistes de btla